Artivion (NYSE:AORT) Issues Quarterly Earnings Results

Artivion (NYSE:AORT - Get Free Report) issued its earnings results on Monday. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51), reports. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $97.31 million during the quarter, compared to analysts' expectations of $100.82 million. Artivion updated its FY 2025 guidance to EPS.

Artivion Stock Down 0.1 %

Shares of AORT traded down $0.02 during trading hours on Friday, hitting $25.34. The company had a trading volume of 568,539 shares, compared to its average volume of 404,014. The company has a market capitalization of $1.06 billion, a PE ratio of -1,267.00 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion has a one year low of $18.38 and a one year high of $32.33. The company's fifty day moving average price is $29.58 and its two-hundred day moving average price is $27.80.

Analyst Upgrades and Downgrades

AORT has been the subject of several research reports. Oppenheimer upped their target price on Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. JMP Securities reissued a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Stifel Nicolaus reduced their price target on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, Needham & Company LLC reduced their price target on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $31.40.

Remove Ads

Insider Activity at Artivion

In related news, VP Andrew M. Green sold 7,618 shares of the company's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now directly owns 33,503 shares of the company's stock, valued at $1,005,090. This represents a 18.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO James P. Mackin sold 42,156 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the transaction, the chief executive officer now directly owns 663,882 shares in the company, valued at $18,130,617.42. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 77,224 shares of company stock valued at $2,162,330 in the last ninety days. Corporate insiders own 8.10% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.